These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

650 related articles for article (PubMed ID: 26382603)

  • 21. Protection of rabbits against challenge with rabbit papillomaviruses by immunization with the N terminus of human papillomavirus type 16 minor capsid antigen L2.
    Gambhira R; Jagu S; Karanam B; Gravitt PE; Culp TD; Christensen ND; Roden RB
    J Virol; 2007 Nov; 81(21):11585-92. PubMed ID: 17715230
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A papillomavirus-like particle (VLP) vaccine displaying HPV16 L2 epitopes induces cross-neutralizing antibodies to HPV11.
    Slupetzky K; Gambhira R; Culp TD; Shafti-Keramat S; Schellenbacher C; Christensen ND; Roden RB; Kirnbauer R
    Vaccine; 2007 Mar; 25(11):2001-10. PubMed ID: 17239496
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Vaccination with multimeric L2 fusion protein and L1 VLP or capsomeres to broaden protection against HPV infection.
    Jagu S; Kwak K; Garcea RL; Roden RB
    Vaccine; 2010 Jun; 28(28):4478-86. PubMed ID: 20434552
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A three component mix of thioredoxin-L2 antigens elicits broadly neutralizing responses against oncogenic human papillomaviruses.
    Seitz H; Canali E; Ribeiro-Müller L; Pàlfi A; Bolchi A; Tommasino M; Ottonello S; Müller M
    Vaccine; 2014 May; 32(22):2610-7. PubMed ID: 24662712
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chimeric L2-Based Virus-Like Particle (VLP) Vaccines Targeting Cutaneous Human Papillomaviruses (HPV).
    Huber B; Schellenbacher C; Shafti-Keramat S; Jindra C; Christensen N; Kirnbauer R
    PLoS One; 2017; 12(1):e0169533. PubMed ID: 28056100
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Incorporation of RG1 epitope into HPV16L1-VLP does not compromise L1-specific immunity.
    Schellenbacher C; Huber B; Skoll M; Shafti-Keramat S; Roden RBS; Kirnbauer R
    Vaccine; 2019 Jun; 37(27):3529-3534. PubMed ID: 31147274
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A pan-HPV vaccine based on bacteriophage PP7 VLPs displaying broadly cross-neutralizing epitopes from the HPV minor capsid protein, L2.
    Tumban E; Peabody J; Peabody DS; Chackerian B
    PLoS One; 2011; 6(8):e23310. PubMed ID: 21858066
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Oral immunization with bacteriophage MS2-L2 VLPs protects against oral and genital infection with multiple HPV types associated with head & neck cancers and cervical cancer.
    Zhai L; Yadav R; Kunda NK; Anderson D; Bruckner E; Miller EK; Basu R; Muttil P; Tumban E
    Antiviral Res; 2019 Jun; 166():56-65. PubMed ID: 30926288
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Chimeric L1-L2 virus-like particles as potential broad-spectrum human papillomavirus vaccines.
    Schellenbacher C; Roden R; Kirnbauer R
    J Virol; 2009 Oct; 83(19):10085-95. PubMed ID: 19640991
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Measurement of neutralizing serum antibodies of patients vaccinated with human papillomavirus L1 or L2-based immunogens using furin-cleaved HPV Pseudovirions.
    Wang JW; Jagu S; Wang C; Kitchener HC; Daayana S; Stern PL; Pang S; Day PM; Huh WK; Roden RB
    PLoS One; 2014; 9(7):e101576. PubMed ID: 24999962
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A novel candidate HPV vaccine: MS2 phage VLP displaying a tandem HPV L2 peptide offers similar protection in mice to Gardasil-9.
    Zhai L; Peabody J; Pang YS; Schiller J; Chackerian B; Tumban E
    Antiviral Res; 2017 Nov; 147():116-123. PubMed ID: 28939477
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Dual-Type L2 11-88 Peptide from HPV Types 16/18 Formulated in Montanide ISA 720 Induced Strong and Balanced Th1/Th2 Immune Responses, Associated with High Titers of Broad Spectrum Cross-Reactive Antibodies in Vaccinated Mice.
    Motavalli Khiavi F; Arashkia A; Golkar M; Nasimi M; Roohvand F; Azadmanesh K
    J Immunol Res; 2018; 2018():9464186. PubMed ID: 29854852
    [No Abstract]   [Full Text] [Related]  

  • 33. A human papillomavirus type 16 vaccine by oral delivery of L1 protein.
    Sasagawa T; Tani M; Basha W; Rose RC; Tohda H; Giga-Hama Y; Azar KK; Yasuda H; Sakai A; Inoue M
    Virus Res; 2005 Jun; 110(1-2):81-90. PubMed ID: 15845258
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A vaccine of L2 epitope repeats fused with a modified IgG1 Fc induced cross-neutralizing antibodies and protective immunity against divergent human papillomavirus types.
    Chen X; Liu H; Zhang T; Liu Y; Xie X; Wang Z; Xu X
    PLoS One; 2014; 9(5):e95448. PubMed ID: 24802101
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Protection of rabbits against cutaneous papillomavirus infection using recombinant tobacco mosaic virus containing L2 capsid epitopes.
    Palmer KE; Benko A; Doucette SA; Cameron TI; Foster T; Hanley KM; McCormick AA; McCulloch M; Pogue GP; Smith ML; Christensen ND
    Vaccine; 2006 Jun; 24(26):5516-25. PubMed ID: 16725236
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only.
    Giannini SL; Hanon E; Moris P; Van Mechelen M; Morel S; Dessy F; Fourneau MA; Colau B; Suzich J; Losonksy G; Martin MT; Dubin G; Wettendorff MA
    Vaccine; 2006 Aug; 24(33-34):5937-49. PubMed ID: 16828940
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Vaccination of healthy volunteers with human papillomavirus type 16 L2E7E6 fusion protein induces serum antibody that neutralizes across papillomavirus species.
    Gambhira R; Gravitt PE; Bossis I; Stern PL; Viscidi RP; Roden RB
    Cancer Res; 2006 Dec; 66(23):11120-4. PubMed ID: 17145854
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Modification of human papillomavirus-like particle vaccine by insertion of the cross-reactive L2-epitopes.
    Kondo K; Ochi H; Matsumoto T; Yoshikawa H; Kanda T
    J Med Virol; 2008 May; 80(5):841-6. PubMed ID: 18360909
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rectal and vaginal immunization of mice with human papillomavirus L1 virus-like particles.
    Fraillery D; Zosso N; Nardelli-Haefliger D
    Vaccine; 2009 Apr; 27(17):2326-34. PubMed ID: 19428847
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Robust In Vitro and In Vivo Neutralization against Multiple High-Risk HPV Types Induced by a Thermostable Thioredoxin-L2 Vaccine.
    Seitz H; Ribeiro-Müller L; Canali E; Bolchi A; Tommasino M; Ottonello S; Müller M
    Cancer Prev Res (Phila); 2015 Oct; 8(10):932-41. PubMed ID: 26170394
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 33.